EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts

Leigh Goedeke, Yina Ma, Rafael C Gaspar, Ali Nasiri, Jieun Lee, Dongyan Zhang, Katrine Douglas Galsgaard, Xiaoyue Hu, Jiasheng Zhang, Nicole Guerrera, Xiruo Li, Traci LaMoia und 11 weitere

Journal of Clinical Investigation · 16.12.2024 · 134 (24)

DOI: 10.1172/jci176708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.12.2024. Verfasst von Leigh Goedeke und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (Endocrinology), Yale School of Medicine, New Haven Connecticut, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Oxidation-Reduction, Glucosides. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous studies highlight the potential for sodium-glucose cotransporter type 2 (SGLT2) inhibitors (SGLT2i) to exert cardioprotective effects in heart failure by increasing plasma ketones and shifting myocardial fuel utilization toward ketone oxidation. However, SGLT2i have multiple in vivo effects and the differential impact of SGLT2i treatment and ketone supplementation on cardiac metabolism remains unclear. Here, using gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–tandem mass spectrometry (LC-MS/MS) methodology combined with infusions of [ 13 C 6 ]glucose or [ 13 C 4 ]βOHB, we demonstrate that acute SGLT2 inhibition with dapagliflozin shifts relative rates of myocardial mitochondrial metabolism toward ketone oxidation, decreasing pyruvate oxidation with little effect on fatty acid oxidation in awake rats. Shifts in myocardial ketone oxidation persisted when plasma glucose levels were maintained. In contrast, acute βOHB infusion similarly augmented ketone oxidation, but markedly reduced fatty acid oxidation and did not alter glucose uptake or pyruvate oxidation. After inducing heart failure, dapagliflozin increased relative rates of ketone and fatty acid oxidation, but decreased pyruvate oxidation. Dapagliflozin increased mitochondrial redox and reduced myocardial oxidative stress in heart failure, which was associated with improvements in left ventricular ejection fraction after 3 weeks of treatment. Thus, SGLT2i have pleiotropic effects on systemic and heart metabolism, which are distinct from ketone supplementation and may contribute to the long-term cardioprotective benefits of SGLT2i.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureOxidation-ReductionGlucosidesBenzhydryl CompoundsMitochondria, HeartAnimalsRatsMaleRats, Sprague-DawleyFatty AcidsMyocardiumPyruvic AcidSodium-Glucose Transporter 2Ketones

Stichwörter der Autor:innen

CardiologyGlucose metabolismIntermediary metabolismMetabolismMitochondria

Substanzen

Sodium-Glucose Transporter 2 InhibitorsdapagliflozinGlucosidesBenzhydryl CompoundsSlc5a2 protein, ratFatty AcidsPyruvic AcidSodium-Glucose Transporter 2Ketones

Autor:innen und Institutionen

  • Department of Internal Medicine (Endocrinology), Yale School of Medicine, New Haven Connecticut, USA.
  • Department of Medicine (Cardiology) and The Cardiovascular Research Institute and.
  • Department of Medicine (Endocrinology) and The Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Internal Medicine (Cardiovascular Medicine) and The Yale Cardiovascular Research Center, Yale School of Medicine, New Haven Connecticut, USA.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Cellular & Molecular Physiology, Yale School of Medicine, New Haven Connecticut, USA.

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NIH NIDDK
  • NHLBI
  • AstraZeneca United States

Zitieren

APA

Goedeke, L., Ma, Y., Gaspar, R. C., Nasiri, A., Lee, J., Zhang, D., Galsgaard, K. D., Hu, X., Zhang, J., Guerrera, N., Li, X., LaMoia, T., Hubbard, B. T., Haedersdal, S., Wu, X., Stack, J., Dufour, S., Butrico, G. M., Kahn, M., …, & Shulman, G. I. (2024). SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. Journal of Clinical Investigation, 134(24). https://doi.org/10.1172/jci176708

Vancouver

Goedeke L, Ma Y, Gaspar RC, Nasiri A, Lee J, Zhang D, et al. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. Journal of Clinical Investigation. 2024;134(24). doi:10.1172/jci176708

BibTeX
@article{Goedeke2024,
  author = {Goedeke, Leigh and Ma, Yina and Gaspar, Rafael C and Nasiri, Ali and Lee, Jieun and Zhang, Dongyan and Galsgaard, Katrine Douglas and Hu, Xiaoyue and Zhang, Jiasheng and Guerrera, Nicole and Li, Xiruo and LaMoia, Traci and Hubbard, Brandon T and Haedersdal, Sofie and Wu, Xiaohong and Stack, John and Dufour, Sylvie and Butrico, Gina Marie and Kahn, Mario and Perry, Rachel J and Cline, Gary W and Young, Lawrence H and Shulman, Gerald I},
  title = {SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {24},
  doi = {10.1172/jci176708}
}
Kostenlos starten →